Volker Schirrmacher

Title: Volker Schirrmacher: Innovator in Cancer Therapy

Introduction

Volker Schirrmacher is a prominent inventor based in Heidelberg, Germany. He has made significant contributions to the field of cancer therapy, holding 2 patents that focus on innovative treatment methods. His work is characterized by a commitment to advancing medical science and improving patient outcomes.

Latest Patents

One of Schirrmacher's latest patents is titled "Multi-modal cancer therapy using viral hitch-hiking." This invention involves an antibody fusion protein that specifically recognizes the surface antigens of the New Castle Disease Virus (NDV) and targets tumor-unspecific T cells or dendritic cells. The patent also encompasses polynucleotides encoding the antibody fusion protein and outlines a method for treating tumors by administering the antibody fusion protein or related components to patients, particularly those with solid tumors.

Another significant patent is "Heparanase-derived peptides for vaccination of tumor patients." This vaccine targets diseases associated with enhanced heparanase expression and activity. It contains a heparanase peptide that binds to HLA molecules, providing a novel approach to cancer vaccination.

Career Highlights

Volker Schirrmacher has worked with notable institutions, including the Deutsches Krebsforschungszentrum (German Cancer Research Center) and his own company, Schirrmacher, Dr., Volker. His career reflects a dedication to research and innovation in oncology.

Collaborations

Throughout his career, Schirrmacher has collaborated with esteemed colleagues such as Philipp Beckhove and Philippe Fournier. These partnerships have contributed to the advancement of his research and the development of his patents.

Conclusion

Volker Schirrmacher's work in cancer therapy exemplifies the impact of innovative thinking in medicine. His patents represent significant advancements in treatment methodologies, showcasing his commitment to improving patient care.